Global Plasmid Purification Market to Reach USD 5.13 Billion by 2034

Introduction

Straits Research today released its highly anticipated report, “Global Plasmid Purification Market Size & Outlook, 2026-2034”. According to Straits Research, the market size is valued at USD 2.07 billion in 2025 and is projected to expand to USD 5.13 billion by 2034, registering a compound annual growth rate (CAGR) of 10.66%.

Market Dynamics

The global plasmid purification market is experiencing steady growth, primarily driven by the rising demand for plasmid DNA in gene therapy, vaccine development, and advanced molecular biology research. Plasmids play a critical role as vectors in gene editing, cell and gene therapies, and mRNA-based vaccines, leading to increased demand from biopharmaceutical companies, contract research organizations, and academic institutes. The rapid expansion of genetic research, along with increased funding for life science R&D and the growing number of clinical trials involving plasmid-based therapeutics, continues to strengthen market growth. Additionally, the demand for high-purity, endotoxin-free plasmid DNA for clinical and commercial applications is accelerating the adoption of advanced purification technologies.

However, the market faces a key restraint in the form of high operational costs and complex manufacturing requirements. Large scale plasmid purification requires specialized infrastructure, skilled personnel, and strict compliance with regulatory and quality standards, especially for GMP-grade plasmid production. These factors notably increase production costs, limiting adoption among small laboratories and emerging biotech firms. On the opportunity front, the market is benefiting from technological advancements and increasing automation in plasmid purification processes. Innovations such as high-throughput systems, single-use technologies, and improved chromatography methods are enhancing yield, purity, and efficiency. These advancements are reducing processing time and contamination risks, making plasmid purification more accessible and scalable. As gene therapy pipelines expand globally, these innovations present strong opportunities for sustained long-term growth.

Key Highlights

• Product & Service: The services segment is expected to register the fastest CAGR of 11.04% during 2026-2034.
• Grade: The transfection grade segment is estimated to grow at the fastest CAGR of 11.34% during the forecast period.
• Application: The cloning & protein expression segment dominated the market in 2025, accounting for 48.65% revenue share.
• End Use: The academic & research institutes segment dominated the market in 2025.
• Regional Insights: North America dominated the market, accounting for 41.12% of market share in 2025, owing to the presence of leading biotechnology and pharmaceutical companies.

Competitive Players

1. Thermo Fisher Scientific, Inc.
2. QIAGEN N.V.
3. Merck KGaA
4. Takara Bio Inc.
5. Promega Corporation
6. Bio-Rad Laboratories, Inc.
7. Agilent Technologies Inc.
8. Illumina, Inc.
9. GenScript Biotech Corporation
10. Sino Biological Inc.
11. New England Biolabs, Inc.
12. Origene Technologies, Inc.
13. InvivoGen
14. Omega Bio-tek, Inc.
15. Norgen Biotek Corp.
16. Lucigen Corporation
17. Mirus Bio LLC
18. PlasmidFactory GmbH & Co. KG
19. ABP Biosciences
20. Lamda Biotech
21. Others

Recent Developments

Segmentation

1. By Product & Service (2026-2034)
   1. Instruments
   2. Kits & Reagents
   3. Services
2. By Grade (2026-2034)
   1. Transfection Grade
   2. Molecular Grade
3. By Application (2026-2034)
   1. Gene Editing
   2. Cloning & Protein Expression
   3. Transfection
   4. Others
4. By End Use (2026-2034)
   1. Pharmaceutical & Biotechnology Companies
   2. Academic & Research Institutes
   3. Contract Research Organizations
5. By Region (2026-2034)
   1. North America
   2. Europe
   3. Asia Pacific
   4. Latin America
   5. The Middle East and Africa